laurabbook@gmail.com

*November 2024* Key Takeaways Datopotamab deruxtecan targets EGFR-mutated advanced NSCLC, showing promising response and disease control rates in the TROPION-Lung05 trial. The TROPION-Lung01 trial showed non-significant overall survival improvement, leading to the withdrawal of the BLA for nonsquamous NSCLC. Safety data indicated that all patients experienced treatment-emergent adverse effects, with…

*October 2024* Abstract Purpose This multicenter, randomized, phase III clinical trial (Northern Radiation Oncology Group of China-002) focused on patients with oligo-organ metastatic non–small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. We aimed to investigate whether first-line concurrent thoracic radiotherapy (TRT) and EGFR-tyrosine kinase inhibitors…

*November 2024* LCRF’s 2024 Scientific Symposium was held November 4 as part of their Lung Cancer Awareness Month activities. Joining the record-breaking group online were event lead and moderator, Kathryn O’Donnell, PhD; chat moderator, Isabel Preeshagul, DO, MBS; and speakers Brendon M. Stiles, MD; Colleen Conner Ziegler; Mark Awad, MD,…

*October 2024* Abstract Purpose This multicenter, randomized, phase III clinical trial (Northern Radiation Oncology Group of China-002) focused on patients with oligo-organ metastatic non–small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. We aimed to investigate whether first-line concurrent thoracic radiotherapy (TRT) and EGFR-tyrosine kinase inhibitors…

*October 2024* In a new study published in Nature Medicine UHN researchers have identified specific DNA changes that can predict a patient’s risk of cancer spreading to the brain, offering new approaches to managing patients and improving health outcomes. The spread of cancer to the brain, known as brain metastasis, significantly reduces…

*November 2024* Highlights •EGFR-TKIs have improved outcomes for patients with EGFR-mutant NSCLC. •Acquired resistance occurs through complex and multifaceted mechanisms. •C797S mutation emerges in 6–12 % of patients treated with first-line osimertinib. •Fourth-generation EGFR-TKIs are active against common and resistance EGFR mutations. •Phase 1/2 clinical trials are ongoing, with promising activity…

*October 2024* Key Takeaways Osimertinib combined with savolitinib shows high response rates in EGFR-mutant, MET-overexpressed/amplified NSCLC patients post-osimertinib progression. The SAVANNAH trial confirms the safety profile of the osimertinib and savolitinib combination, with no new safety signals reported Fast track designation by the FDA underscores the potential of this combination…

*October 2024* Key Points: In EGFR-mutated non–small cell lung cancer (NSCLC), treatment with the tyrosine kinase inhibitor (TKI) osimertinib has routinely demonstrated superior survival rates; however, resistance is inevitable. MET deregulation, including the amplification of the gene (METamp), is the most common mechanism of osimertinib resistance. Dual anti-EGFR/anti-MET inhibition may be an…